Tekmira (TKMR) Narrows FY11 Loss on Lighter Sales; Sees Flat FY12 Revs
Tweet
Share
E-mailGet Alerts TKMR Hot Sheet
Join SI Premium – FREE
Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR) reports a loss of 88 cents per share for FY11, compared with a loss of $1.20 for the same period in the prior year. Revs were $16.6 million, down from $21.4 million in 2010.
Looking ahead, Tekmire sees total revenue at a similar level in 2012 as in 2011. Tekmira expects U.S. Government contract revenue to increase over 2011 levels; however, this will be offset by lower expected 2012 Alnylam revenue as compared to 2011.
Looking ahead, Tekmire sees total revenue at a similar level in 2012 as in 2011. Tekmira expects U.S. Government contract revenue to increase over 2011 levels; however, this will be offset by lower expected 2012 Alnylam revenue as compared to 2011.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue
- Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
